The go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug